MEI Pharma Inc

The Audit Committee has selected Deloitte & Touche LLP (Deloitte) as independent registered public accounting firm to audit the financial statements of the Company for the fiscal year ending June 30, 2025. The Board is submitting the appointment of Deloitte to the stockholders for ratification as a matter of good corporate practice.

Deloitte has been engaged as the Company’s independent auditor since December 26, 2023. They performed the Company’s annual audit of its financial statements for the fiscal year ended June 30, 2024. BDO USA, P.C. (BDO) served as the independent registered public accounting firm for the Company for the period from January 18, 2011 through the fiscal year ended June 30, 2023 and the subsequent interim period ended September 30, 2023. BDO’s report did not contain an adverse opinion or disclaimer of option nor was it qualified or modified as to uncertainty, audit scope, or accounting principles. On December 19, 2023, our Audit Committee approved the change in our independent registered public accounting firm effective December 26, 2023 to Deloitte.

Representatives of Deloitte are expected to attend the Annual Meeting. The Deloitte representatives will have an opportunity to make a statement at the meeting and are expected to be available to respond to appropriate questions.